Literature DB >> 1314868

Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection.

S K Burchett1, L Corey, K M Mohan, J Westall, R Ashley, C B Wilson.   

Abstract

Interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha production and lymphocyte proliferation in response to herpes simplex virus (HSV) antigen were assessed in 13 neonates and 3 parturient women with primary HSV infection. In comparison with 9 nonparturient adults, the neonates and parturient women showed significantly (P less than .01) diminished HSV antigen-stimulated lymphocyte proliferation and IFN-gamma production in the first 3-6 weeks after onset of infection. TNF alpha production did not differ significantly among HSV-infected groups. The impairment in neonatal cellular immunity was due, at least in part, to a specific deficit in response to HSV antigen. Lymphocyte proliferation and TNF alpha production in response to the mitogen concanavalin A (ConA) were comparable in adults and infants, but ConA-stimulated IFN-gamma production in infants was diminished throughout the study period. In contrast, HSV antigen-stimulated IFN-gamma production was comparable in infants and adults after 6 weeks. Not all patients with diminished cellular immune responses to HSV antigen manifested severe clinical disease. Nevertheless, patients with significant clinical morbidity had diminished cellular immune responses to HSV antigen. These results suggest that delayed acquisition of antigen-specific cellular immunity in primary HSV infection predisposes to more severe clinical disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314868     DOI: 10.1093/infdis/165.5.813

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Neonatal innate immunity to infectious agents.

Authors:  László Maródi
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 4.  Vaccination strategies to enhance immunity in neonates.

Authors:  Tobias R Kollmann; Arnaud Marchant; Sing Sing Way
Journal:  Science       Date:  2020-05-08       Impact factor: 47.728

Review 5.  T cell-mediated immune responses in human newborns: ready to learn?

Authors:  A Marchant; M Goldman
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

6.  Developmental regulation of Th17-cell capacity in human neonates.

Authors:  Allison Black; Suniti Bhaumik; Richard L Kirkman; Casey T Weaver; David A Randolph
Journal:  Eur J Immunol       Date:  2011-12-19       Impact factor: 5.532

7.  Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection.

Authors:  K H Edelmann; C B Wilson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Intrastrain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness.

Authors:  J R Bower; H Mao; C Durishin; E Rozenbom; M Detwiler; D Rempinski; T L Karban; K S Rosenthal
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 9.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

10.  Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.

Authors:  Aziz Alami Chentoufi; Nicholas R Binder; Noureddine Berka; Guillaume Durand; Alex Nguyen; Ilham Bettahi; Bernard Maillère; Lbachir BenMohamed
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.